Advertisement

September 16, 2020

AOTI’s Topical Wound Oxygen Product Line Expanded for Treating Larger Limbs

September 16, 2020—Advanced Oxygen Therapy, Inc. (AOTI) announced an expansion of its multimodality Topical Wound Oxygen (TWO2) therapy product family with the addition of a new larger-extremity chamber for the treatment of nonhealing chronic wounds in patients with peripheral vascular disease. The new device is designed to address the needs of those patients with larger limbs, those with venous leg ulcers being treated by conventional compression dressings (CCD) or Unna boots, or those with diabetic foot ulcers being offloaded using a total contact cast (TCC).

According to the company, TWO2 therapy is beneficial in the treatment of edematous wounds by providing cyclical-pressure oxygen to help reduce edema via noncontact compression. TWO2 has been shown to reduce inflammation and help combat infection, thereby stimulating angiogenesis, while promoting better-quality collagen synthesis, resulting in more robust and durable wound healing for up to 36 months.

TWO2 treatments are applied at home without the need to remove gas permeable dressings, with oxygen diffusing easily through CCD, Unna boots, and TCC adjunctive treatments. AOTI also provides the prescriber with “eyes on the wound” telehealth feedback, allowing for both healing and wound protective care to be delivered safely for patients at home.

Advertisement


September 16, 2020

Vesalio Expands International Distribution of NeVa Thrombectomy System

September 16, 2020

Safety and Survival Data Presented From CIRT-EU Registry of Sirtex SIR-Spheres Therapy